- Risankizumab in first-line treatment of psoriasis2022 | Faculty of Medicine in Pilsen
- Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells2014 | Second Faculty of Medicine
- Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities2022 | Second Faculty of Medicine, First Faculty of Medicine
- Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab2021 | Third Faculty of Medicine
- News in the biological treatment of psoriatic arthritis2015 | First Faculty of Medicine
- Is chronic plaque psoriasis triggered by microbiota in the skin?2013 | Faculty of Medicine in Pilsen
- Modulation of IL-12/IL-23 signaling pathways by ustekinumab alleviates inflammation in Crohn's disease patients2018 | Faculty of Medicine in Hradec Králové
- p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+T-cells2017 | Second Faculty of Medicine
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial2020 | Faculty of Medicine in Pilsen